Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder

Mette Kruse Klausen; Gitte Moos Knudsen; Tina Vilsbøll; Anders Fink-Jensen

doi:10.1111/bcpt.70004

Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder

Mette Kruse Klausen, Gitte Moos Knudsen, Tina Vilsbøll, Anders Fink-Jensen

Publikation: Bidrag til tidsskrift › Review › peer review

5 Downloads (Pure)

Abstract

In the search for novel treatment strategies for alcohol use disorder (AUD), glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) approved for treating Type 2 diabetes and obesity have caught much attention. GLP-1 is a naturally occurring peptide produced in the small intestines and the brain, regulating plasma glucose levels and satiety. This focused review will report on the preclinical studies, case stories, register-based cohort studies, brain-imaging data and secondary analysis of clinical data supporting the role of GLP-1RAs as a novel treatment of AUD. Several clinical trials are ongoing, examining the potential effects of the GLP-1RA semaglutide in AUD.

Originalsprog	Engelsk
Artikelnummer	e70004
Tidsskrift	Basic & clinical pharmacology & toxicology
Vol/bind	136
Udgave nummer	3
Antal sider	15
ISSN	1742-7835
DOI	https://doi.org/10.1111/bcpt.70004
Status	Udgivet - 2025

Bibliografisk note

Adgang til dokumentet

10.1111/bcpt.70004Licens: CC BY-NC-ND

FulltextForlagets udgivne version, 547 KBLicens: CC BY-NC-ND

Citationsformater

@article{b2d22e7cbb9f4bc08500a74e0a5bfeda,

title = "Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder",

abstract = "In the search for novel treatment strategies for alcohol use disorder (AUD), glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) approved for treating Type 2 diabetes and obesity have caught much attention. GLP-1 is a naturally occurring peptide produced in the small intestines and the brain, regulating plasma glucose levels and satiety. This focused review will report on the preclinical studies, case stories, register-based cohort studies, brain-imaging data and secondary analysis of clinical data supporting the role of GLP-1RAs as a novel treatment of AUD. Several clinical trials are ongoing, examining the potential effects of the GLP-1RA semaglutide in AUD.",

keywords = "Humans, Glucagon-Like Peptide-1 Receptor, Alcoholism/drug therapy, Animals, Glucagon-Like Peptides/therapeutic use, Brain/drug effects, Glucagon-Like Peptide-1 Receptor Agonists",

author = "Klausen, {Mette Kruse} and Knudsen, {Gitte Moos} and Tina Vilsb{\o}ll and Anders Fink-Jensen",

note = "{\textcopyright} 2025 The Author(s). Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).",

year = "2025",

doi = "10.1111/bcpt.70004",

language = "English",

volume = "136",

journal = "Basic and Clinical Pharmacology and Toxicology",

issn = "1742-7835",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder

AU - Klausen, Mette Kruse

AU - Knudsen, Gitte Moos

AU - Vilsbøll, Tina

AU - Fink-Jensen, Anders

N1 - © 2025 The Author(s). Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

PY - 2025

Y1 - 2025

N2 - In the search for novel treatment strategies for alcohol use disorder (AUD), glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) approved for treating Type 2 diabetes and obesity have caught much attention. GLP-1 is a naturally occurring peptide produced in the small intestines and the brain, regulating plasma glucose levels and satiety. This focused review will report on the preclinical studies, case stories, register-based cohort studies, brain-imaging data and secondary analysis of clinical data supporting the role of GLP-1RAs as a novel treatment of AUD. Several clinical trials are ongoing, examining the potential effects of the GLP-1RA semaglutide in AUD.

AB - In the search for novel treatment strategies for alcohol use disorder (AUD), glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) approved for treating Type 2 diabetes and obesity have caught much attention. GLP-1 is a naturally occurring peptide produced in the small intestines and the brain, regulating plasma glucose levels and satiety. This focused review will report on the preclinical studies, case stories, register-based cohort studies, brain-imaging data and secondary analysis of clinical data supporting the role of GLP-1RAs as a novel treatment of AUD. Several clinical trials are ongoing, examining the potential effects of the GLP-1RA semaglutide in AUD.

KW - Humans

KW - Glucagon-Like Peptide-1 Receptor

KW - Alcoholism/drug therapy

KW - Animals

KW - Glucagon-Like Peptides/therapeutic use

KW - Brain/drug effects

KW - Glucagon-Like Peptide-1 Receptor Agonists

U2 - 10.1111/bcpt.70004

DO - 10.1111/bcpt.70004

M3 - Review

C2 - 39891507

VL - 136

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

SN - 1742-7835

IS - 3

M1 - e70004

ER -